Print
Email
Print Edition StoriesMonday, January 4, 2010
Boston Scientific enrolls first patient for stent study
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Robotic surgery gains traction
Funding drugs for rare diseases
Natick medical devices giant Boston Scientific Corp. has enrolled its first patient in a post-approval study of its Taxus Liberte Stent. The study is intended to provide results on the use of aspirin and Effient, an antiplatelet medicine, alongside the Taxus Liberte Paclitaxel-Eluting Coronary Stent System.
The first patient enrolled at Ingham Regional Medical Center in Michigan, and Boston Scientific officials noted in a press release that up to 4,200 patients with coronary artery disease will participate in the study, which will take place at up to 65 sites in the U.S.
The study is expected to show the 12-month rate of cardiac death or myocardial infarction, as well as the five-year rate of stent thrombosis.
Boston Scientific (NYSE: BSX) will issue preliminary data from 1,524 patients enrolled in the study to the joint effort, DAPT (dual antiplatelet therapy) Study, in collaboration with the FDA, drug and device manufacturers and the Harvard Clinical Research Institute (HCRI).
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
